Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 1/20 | 0.41 |
| ▸ | JAK1 | P23458 | 2/20 | 0.39 |
| ▸ | MAP3K5 | Q99683 | 6/20 | 0.38 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.37 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.37 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.36 |
| ▸ | TGFBR2 | P37173 | 2/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.35 |
| ▸ | IGF1R | P08069 | 1/20 | 0.35 |
| ▸ | GRM5 | P41594 | 1/20 | 0.35 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.35 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.35 |
| ▸ | NAMPT | P43490 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4167336 | 0.97 | NR1H2 (0.41) | ESR2JAK1MAP3K5ROCK2NR1H2 | |
| SCHEMBL4152453 | 0.85 | JAK1 (0.50) | JAK1CYP11B2GRM5NAMPT | |
| SCHEMBL3726133 | 0.79 | ROCK2 (0.39) | JAK1ROCK2TGFBR1TGFBR2 | |
| SCHEMBL4157859 | 0.78 | TGFBR1 (0.41) | TGFBR1TGFBR2 | |
| SCHEMBL4165667 | 0.77 | TGFBR1 (0.39) | JAK1TGFBR1TGFBR2 | |
| SCHEMBL4159014 | 0.77 | PLK4 (0.44) | TGFBR1TGFBR2 | |
| SCHEMBL3669196 | 0.77 | MAP3K11 (0.46) | TGFBR1TGFBR2 | |
| SCHEMBL3718462 | 0.76 | TGFBR1 (0.38) | ROCK2TGFBR1TGFBR2 | |
| SCHEMBL4149812 | 0.76 | TGFBR1 (0.41) | MAP3K5TGFBR1TGFBR2 | |
| SCHEMBL3724252 | 0.76 | TGFBR1 (0.45) | TGFBR1TGFBR2NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8314112-B2 | Pyrrolopyrimidines and pyrrolopyridines | NOVARTIS AG (CH) | 2012-11-20 | — | — | US | disclosed |
| US-20090181941-A1 | Pyrrolopyrimidines and Pyrrolopyridines | NOVARTIS AG (CH) | 2009-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090181941-A1 | Pyrrolopyrimidines and Pyrrolopyridines | ALK, ACVR1, PTPN4 | ESR2 2588/4885JAK1 29/4885MAP3K5 248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.